Keywords
Last Name
Institution

Christina Voelkel Johnson

Title
InstitutionMedical University of South Carolina
DepartmentMicrobiology and Immunology
AddressP.O. Box MSC 955
HO352
Hollings Cancer Center - 86 Jonathan Lucas St.
Phone843-792-3125
Fax843-792-9588
vCardDownload vCard

    Collapse Overview 
    Collapse studies/trials
    Collapse keywords
    Cancer, Sphingolipids, Cell Death

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Voelkel-Johnson C. Sphingolipids in embryonic development, cell cycle regulation, and stemness - Implications for polyploidy in tumors. Semin Cancer Biol. 2021 Jan 08. PMID: 33429049.
      View in: PubMed
    2. White-Gilbertson S, Davis M, Voelkel-Johnson C, Kasman LM. Sex differences in the MB49 syngeneic, murine model of bladder cancer. Bladder (San Franc). 2016; 3(1). PMID: 26998503.
      View in: PubMed
    3. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. . 2015 Dec; 14(12):2744-52. PMID: 26494858.
      View in: PubMed
    4. Tirodkar TS, Lu P, Bai A, Scheffel MJ, Gencer S, Garrett-Mayer E, Bielawska A, Ogretmen B, Voelkel-Johnson C. Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner. J Biol Chem. 2015 May 22; 290(21):13157-67. PMID: 25839235.
      View in: PubMed
    5. Rajagopalan V, Canals D, Luberto C, Snider J, Voelkel-Johnson C, Obeid LM, Hannun YA. Critical determinants of mitochondria-associated neutral sphingomyelinase (MA-nSMase) for mitochondrial localization. Biochim Biophys Acta. 2015 Apr; 1850(4):628-39. PMID: 25484313.
      View in: PubMed
    6. Sundaram K, Sambandam Y, Balasubramanian S, Pillai B, Voelkel-Johnson C, Ries WL, Reddy SV. STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells. Bone. 2015 Feb; 71:137-44. PMID: 25445452.
      View in: PubMed
    7. Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga OS, Simms P, Beeson G, Voelkel-Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S. Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res. 2014 Nov 01; 74(21):6036-6047. PMID: 25164014.
      View in: PubMed
    8. Dai L, Plaisance-Bonstaff K, Voelkel-Johnson C, Smith CD, Ogretmen B, Qin Z, Parsons C. Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells. PLoS One. 2014; 9(7):e102314. PMID: 25010828.
      View in: PubMed
    9. Gosnell H, Kasman LM, Potta T, Vu L, Garrett-Mayer E, Rege K, Voelkel-Johnson C. Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. J Control Release. 2014 Feb 28; 176:35-43. PMID: 24370892.
      View in: PubMed
    10. Kasman L, Voelkel-Johnson C. An orthotopic bladder cancer model for gene delivery studies. J Vis Exp. 2013 Dec 01; (82):50181. PMID: 24326612.
      View in: PubMed
    11. Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, Voelkel-Johnson C, Smith CD, Ogretmen B, Parsons C. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. . 2014 Jan; 13(1):154-64. PMID: 24140934.
      View in: PubMed
    12. May LA, Kramarenko II, Brandon CS, Voelkel-Johnson C, Roy S, Truong K, Francis SP, Monzack EL, Lee FS, Cunningham LL. Inner ear supporting cells protect hair cells by secreting HSP70. J Clin Invest. 2013 Aug; 123(8):3577-87. PMID: 23863716.
      View in: PubMed
    13. Tirodkar TS, Voelkel-Johnson C. Sphingolipids in apoptosis. Exp Oncol. 2012 Oct; 34(3):231-42. PMID: 23070008.
      View in: PubMed
    14. Brandon CS, Voelkel-Johnson C, May LA, Cunningham LL. Dissection of adult mouse utricle and adenovirus-mediated supporting-cell infection. J Vis Exp. 2012 Mar 28; (61). PMID: 22491073.
      View in: PubMed
    15. Kasman L, Onicescu G, Voelkel-Johnson C. Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells. Prostate Cancer. 2012; 2012:137163. PMID: 22288017.
      View in: PubMed
    16. Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol. 2011 Jun 14; 8(8):417-27. PMID: 21670755.
      View in: PubMed
    17. Kaur N, Naga OS, Norell H, Al-Khami AA, Scheffel MJ, Chakraborty NG, Voelkel-Johnson C, Mukherji B, Mehrotra S. T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules. Cytokine. 2011 Aug; 55(2):307-17. PMID: 21602054.
      View in: PubMed
    18. Murali A, Kasman L, Voelkel-Johnson C. Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer. BMC Cancer. 2011 May 12; 11:168. PMID: 21569442.
      View in: PubMed
    19. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. . 2010 Aug; 9(8):2220-31. PMID: 20682655.
      View in: PubMed
    20. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010 Aug 01; 70(15):6313-24. PMID: 20631069.
      View in: PubMed
    21. Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. . 2010 May; 9(5):1378-95. PMID: 20442308.
      View in: PubMed
    22. Kasman LM, Barua S, Lu P, Rege K, Voelkel-Johnson C. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009 Sep-Oct; 6(5):1612-9. PMID: 19655763.
      View in: PubMed
    23. Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res. 2009 Aug 01; 69(15):6282-9. PMID: 19638595.
      View in: PubMed
    24. White-Gilbertson SJ, Kasman L, McKillop J, Tirodkar T, Lu P, Voelkel-Johnson C. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. J Urol. 2009 Sep; 182(3):1178-85. PMID: 19625063.
      View in: PubMed
    25. White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. Mol Oncol. 2009 Dec; 3(5-6):402-8. PMID: 19546037.
      View in: PubMed
    26. Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol. 2009 Aug; 76(2):342-55. PMID: 19483104.
      View in: PubMed
    27. Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, Fisher PB, Dent P. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. . 2009 May; 8(5):1280-91. PMID: 19417161.
      View in: PubMed
    28. Voelkel-Johnson C. Combination therapy with TRAIL: Recent developments and potential pitfalls. . 2009 Jan; 8(1):81-3. PMID: 19127121.
      View in: PubMed
    29. White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L, Voelkel-Johnson C. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene. 2009 Feb 26; 28(8):1132-41. PMID: 19137010.
      View in: PubMed
    30. Mehrotra S, Mougiakakos D, Johansson CC, Voelkel-Johnson C, Kiessling R. Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res. 2009; 102:197-227. PMID: 19595310.
      View in: PubMed
    31. White-Gilbertson S, Rubinchik S, Voelkel-Johnson C. Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev. 2008 Apr; 19(2):167-72. PMID: 18353705.
      View in: PubMed
    32. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, Voelkel-Johnson C. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med. 2007 Nov 01; 43(9):1313-21. PMID: 17893044.
      View in: PubMed
    33. Kasman L, Lu P, Voelkel-Johnson C. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007 Mar; 14(3):327-34. PMID: 17186014.
      View in: PubMed
    34. White SJ, Lu P, Keller GM, Voelkel-Johnson C. Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. . 2006 Dec; 5(12):1618-23. PMID: 17106251.
      View in: PubMed
    35. White SJ, Voelkel-Johnson C. Illuminating TRAIL gene therapy. . 2006 Nov; 5(11):1521-2. PMID: 17204862.
      View in: PubMed
    36. Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S, Dong JY, McKillop J, Norris K, Obeid L, Rubinchik S, Tavassoli M, Tomlinson S, Voelkel-Johnson C, Liu X. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51. PMID: 16763610.
      View in: PubMed
    37. El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther. 2006 Mar; 13(3):281-9. PMID: 16167063.
      View in: PubMed
    38. Voelkel-Johnson C, Hannun YA, El-Zawahry A. Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. . 2005 Sep; 4(9):1320-7. PMID: 16170023.
      View in: PubMed
    39. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005 Jan 07; 5:2. PMID: 15638938.
      View in: PubMed
    40. Sudarshan S, Holman DH, Hyer ML, Voelkel-Johnson C, Dong JY, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8. PMID: 15514684.
      View in: PubMed
    41. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22. PMID: 14605667.
      View in: PubMed
    42. Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. . 2003 May-Jun; 2(3):283-90. PMID: 12878867.
      View in: PubMed
    43. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. . 2002 Sep-Oct; 1(5):520-7. PMID: 12496481.
      View in: PubMed
    44. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72. PMID: 11857034.
      View in: PubMed
    45. Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S, Dong JY. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36. PMID: 12109135.
      View in: PubMed
    46. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther. 2000 Oct; 2(4):348-58. PMID: 11020350.
      View in: PubMed
    47. Voelkel-Johnson C, Voeks DJ, Greenberg NM, Barrios R, Maggouta F, Kurtz DT, Schwartz DA, Keller GM, Papenbrock T, Clawson GA, Norris JS. Genomic instability-based transgenic models of prostate cancer. Carcinogenesis. 2000 Aug; 21(8):1623-7. PMID: 10910968.
      View in: PubMed
    48. O'Brien JB, Piddington DL, Voelkel-Johnson C, Richards DJ, Hadley LA, Laster SM. Sustained phosphorylation of cytosolic phospholipase A2 accompanies cycloheximide- and adenovirus-induced susceptibility to TNF. J Immunol. 1998 Aug 01; 161(3):1525-32. PMID: 9686620.
      View in: PubMed
    49. Thorne TE, Voelkel-Johnson C, Casey WM, Parks LW, Laster SM. The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor. J Virol. 1996 Dec; 70(12):8502-7. PMID: 8970973.
      View in: PubMed
    50. Voelkel-Johnson C, Thorne TE, Laster SM. Susceptibility to TNF in the presence of inhibitors of transcription or translation is dependent on the activity of cytosolic phospholipase A2 in human melanoma tumor cells. J Immunol. 1996 Jan 01; 156(1):201-7. PMID: 8598463.
      View in: PubMed
    51. Voelkel-Johnson C, Entingh AJ, Wold WS, Gooding LR, Laster SM. Activation of intracellular proteases is an early event in TNF-induced apoptosis. J Immunol. 1995 Feb 15; 154(4):1707-16. PMID: 7836755.
      View in: PubMed
    52. Zilli D, Voelkel-Johnson C, Skinner T, Laster SM. The adenovirus E3 region 14.7 kDa protein, heat and sodium arsenite inhibit the TNF-induced release of arachidonic acid. Biochem Biophys Res Commun. 1992 Oct 15; 188(1):177-83. PMID: 1417842.
      View in: PubMed
    Johnson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description